Stay updated on BI 1323495 Dose Tolerance & Inflammation Biomarkers Clinical Trial
Sign up to get notified when there's something new on the BI 1323495 Dose Tolerance & Inflammation Biomarkers Clinical Trial page.
Latest updates to the BI 1323495 Dose Tolerance & Inflammation Biomarkers Clinical Trial page
- Check6 days agoChange DetectedNew guidelines for sharing raw clinical study data and documents sponsored by Boehringer Ingelheim have been added, detailing exceptions and providing a link for more information, while several previous access criteria and sharing agreements have been removed.SummaryDifference11%
- Check13 days agoChange DetectedThe website has added new features for user interaction while removing extensive details about participant groups, interventions, and various data fields available for download.SummaryDifference4%
- Check21 days agoChange DetectedThe study has been terminated as of November 5, 2024, with new results posted detailing participant groups, drug-related adverse events, and various changes from baseline in neutrophil activity and counts, while previous entries regarding completed status and specific locations have been removed.SummaryDifference44%
- Check35 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check43 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.2%
- Check64 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
Stay in the know with updates to BI 1323495 Dose Tolerance & Inflammation Biomarkers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BI 1323495 Dose Tolerance & Inflammation Biomarkers Clinical Trial page.